QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors
Public ClinicalTrials.gov record NCT03228667. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
QUILT-3.055: A Phase IIb, Multicohort, Open-Label Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With PD-1/PD-L1 Immune Checkpoint Inhibitors
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
QUILT-3.055 is a Phase 2b, open-label, multicohort study investigating combination immunotherapies in patients with advanced solid tumors who have previously been treated with PD-1/PD-L1 checkpoint inhibitors. The study aims to evaluate the safety and efficacy of NAI (nogapendekin alfa inbakicept) in combination with other agents like checkpoint inhibitors and cell therapies across various cancer types and treatment settings. The study includes multiple cohorts based on prior therapies and cancer types, with a focus on assessing overall response rate (ORR), overall survival (OS), and other measures of anti-tumor activity and immune response.
Study identification
- NCT ID
- NCT03228667
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 40 participants
Conditions and interventions
Conditions
Interventions
- N-803 + Pembrolizumab Drug
- N-803 + Nivolumab Drug
- N-803 + Atezolizumab Drug
- N-803 + Avelumab Drug
- N-803 + Durvalumab Drug
- N-803 + Pembrolizumab + PD-L1 t-haNK Drug
- N-803 + Nivolumab + PD-L1 t-haNK Drug
- N-803 + Atezolizumab + PD-L1 t-haNK Drug
- N-803 + Avelumab + PD-L1 t-haNK Drug
- N-803 + Durvalumab + PD-L1 t-haNK Drug
- N-803 + Docetaxel + Pembrolizumab Drug
- N-803 + Docetaxel + Nivolumab Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 11, 2018 (Actual)
- Primary completion
- Aug 31, 2029 (Estimated)
- Completion
- Dec 31, 2030 (Estimated)
- Last update posted
- Jan 14, 2026
2018 – 2030
United States locations
- U.S. sites
- 35
- U.S. states
- 23
- U.S. cities
- 34
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Alaska Clinical Research Center | Anchorage | Alaska | 99530 | — |
| Genesis Cancer Center | Hot Springs | Arkansas | 71913 | — |
| Chan Soon-Shiong Institute for Medicine | El Segundo | California | 90245 | — |
| MemorialCare Health System | Fountain Valley | California | 37846 | — |
| Glendale Adventist Medical Center | Glendale | California | 91206 | — |
| University of Southern California Norris Comprehensive Cancer Center | Los Angeles | California | 90033 | — |
| Desert Hematology Oncology Medical Group, Inc. | Rancho Mirage | California | 92270 | — |
| Memorial Healthcare System | Hollywood | Florida | 33021 | — |
| Miami Cancer Institute (Baptist Health South Florida) | Miami | Florida | 33176 | — |
| University of Miami | Miami | Florida | 33180 | — |
| Horizon Oncology Associates | Lafayette | Indiana | 47905 | — |
| University of Iowa Holden Comprehensive Cancer Center | Iowa City | Iowa | 52242 | — |
| Baptist Health - Lexington | Lexington | Kentucky | 40503 | — |
| Baptist Health- Louisville | Louisville | Kentucky | 40207 | — |
| Dana Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| Henry Ford Hospital | Detroit | Michigan | 48202 | — |
| University of Minnesota - Masonic Cancer Center | Minneapolis | Minnesota | 55455 | — |
| Mercy Research Joplin | Joplin | Missouri | 64804 | — |
| Mercy Clinic Cancer & Hematology - Chub O'Reilly Cancer Center | Springfield | Missouri | 65804 | — |
| Washington University School of Medicine | St Louis | Missouri | 63110 | — |
| St. Vincent Frontier Cancer Center (SCL) | Billings | Montana | 59102 | — |
| Dartmouth-Hitchcock Medical Center | Lebanon | New Hampshire | 03756 | — |
| Roswell Park Cancer Institute | Buffalo | New York | 14263 | — |
| University of Rochester | Rochester | New York | 14642 | — |
| Cleveland Clinic - Main Site | Cleveland | Ohio | 44195 | — |
| Mercy Clinic Oklahoma City | Oklahoma City | Oklahoma | 73120 | — |
| Providence Portland Medical Center | Portland | Oregon | 97213 | — |
| Gettysburg/Hanover Cancer Centers | Gettysburg | Pennsylvania | 17325 | — |
| Medical University of South Carolina | Charleston | South Carolina | 29425 | — |
| St. Francis Cancer Center/Bon Secours St. Francis Health System | Greenville | South Carolina | 29607 | — |
| Spartanburg Medical Center | Spartanburg | South Carolina | 29303 | — |
| Sanford Clinical Research | Sioux Falls | South Dakota | 57104 | — |
| University of Tennessee Medical Center | Knoxville | Tennessee | 37920 | — |
| Oncology Consultants of Houston | Houston | Texas | 77024 | — |
| Bon Secours Richmond | Richmond | Virginia | 23114 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03228667, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 14, 2026 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03228667 live on ClinicalTrials.gov.